The dual agonist mechanism distinguishes tirzepatide from earlier GLP-1 receptor agonists such as semaglutide or dulaglutide
[DOI] [PubMed] [Google Scholar] 71.abuzek K., Kozowski M., Szkudapski D., Sikorska P., Kozowska M., Okopie B
However, it is documented in the prescribing information that patients treated with GLP-1 receptor agonists report gastrointestinal adverse events at a significantly higher rate than patients treated with a placebo
But in the two semaglutide plus trevogrumab groups, this percentage was 17%, while people in the full combination group saw just a 7% loss of lean body mass
Why Choose Avere Beauty for Semaglutide in Pittsburgh
Dont forget to book an Injection Bar to boost your next event